Amedisys Chief Medical Officer, Michael Fleming, MD, FAAFP Applauds The Lancet Global Burden of Disease Study

  Amedisys Chief Medical Officer, Michael Fleming, MD, FAAFP Applauds The
  Lancet Global Burden of Disease Study

Business Wire

BATON ROUGE, La. -- December 21, 2012

Amedisys Inc.(NASDAQ: AMED), a national leader in health care at home
companies applauded the Global Burden of Disease Study published by British
journal, The Lancet.

The study features results from a new 10-year look at the Global Burden of
Disease, and not at all surprisingly the biggest contributor to the global
health burden is the specter of chronic diseases. With life expectancy
climbing in the U.S., so too are the number of years people will live with
diseases like high blood pressure, diabetes, cardiovascular disease and mental
health disorders.

“This remarkable shift calls for a paradigm change for healthcare delivery in
the U.S.,” says Michael Fleming, MD, FAAFP and Chief Medical Officer for
Amedisys. “In our view, only through an approach that cares for patients on a
sustained basis -- around the clock and year-round -- can our healthcare
delivery system properly manage those chronic diseases. We must move from a
short-term episodic care mindset to one that can better manage chronic disease
and prevent costly exacerbations – a longitudinal care model.”

To read the full blog post by Dr. Fleming on this paradigm shift in health
care, please visit:
http://www.amedisys.com/Our-Company/Health-Care-At-Home-Blog/December-2012/Longitudinal-Chronic-Care-Needed-to-Reduce-Burden

To read the entire Global Burden of Disease Study, please click here.

About Amedisys:

Amedisys, Inc. (NASDAQ: AMED) is a leading health care at home company
delivering personalized home health and hospice care to more than 360,000
patients each year. Amedisys is focused on delivering the care that is best
for our patients, whether that is home-based recovery and rehabilitation after
an operation or injury, care focused on empowering them to manage a chronic
disease, palliative care for those with a terminal illness, or hospice care at
the end of life. The Company's state-of-the-art advanced chronic care
management programs and leading-edge technology enables it to deliver quality
care based upon the latest evidence-based best practices. Amedisys is a
recognized innovator, being one of the first in the industry to equip its
clinicians with point-of-care laptop technology and referring physicians with
an internet portal that enables real-time coordination of patient care
seamlessly. Amedisys also has the industry's first-ever nationwide Care
Transitions program, designed to reduce unnecessary hospital readmissions
through patient and caregiver health coaching and care coordination, which
starts in the hospital and continues throughout completion of the patient's
home health plan of care. For more information about the Company, please
visit: http://www.amedisys.com.

Contact:

Amedisys Inc.
Jacqueline Chen Valencia, 225-299-3688
Marketing & Communications
jacqueline.chen@amedisys.com